Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Hauns · SciRah

Researcher profile · Semantic Scholar

B. Hauns

Share profile

B. Hauns — researcher profile on SciRah

h-index: 15
Works: 48
Citations: 979

Most-cited papers

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
M. Bitzer, M. Horger, E. Giannini, T. Ganten +21 more
2016Journal of Hepatology135 citations
Semantic Scholar
Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity
Anna Westlind-Johnsson, R. Hermann, A. Huennemeyer, B. Hauns +5 more
2006Clinical pharmacology and therapy121 citations
Semantic Scholar
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
C. Buske, A. Tedeschi, J. Trotman, R. García-Sanz +16 more
2021Journal of Clinical Oncology106 citations Open access
Semantic Scholar
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
A. Noy, S. de Vos, M. Coleman, P. Martin +15 more
2020Blood Advances98 citations Open access
Semantic Scholar
Dose‐Proportional Intraindividual Single‐ and Repeated‐Dose Pharmacokinetics of Roflumilast, an Oral, Once‐Daily Phosphodiesterase 4 Inhibitor
T. Bethke, G. Böhmer, R. Hermann, B. Hauns +6 more
2007Journal of clinical pharmacology86 citations
Semantic Scholar
The pharmacokinetics of a 1-h paclitaxel infusion
K. Mross, N. Holländer, B. Hauns, Martin Schumacher +1 more
2000Cancer Chemotherapy and Pharmacology56 citations
Semantic Scholar
First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
A. Brunetto, J. Ang, R. Lal, D. Olmos +10 more
2013Clinical Cancer Research52 citations Open access
Semantic Scholar
Investigation of a Potential Food Effect on the Pharmacokinetics of Roflumilast, an Oral, Once‐Daily Phosphodiesterase 4 Inhibitor, in Healthy Subjects
B. Hauns, R. Hermann, A. Hünnemeyer, R. Herzog +3 more
2006Journal of clinical pharmacology45 citations
Semantic Scholar
Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
Eric Brouwer, J. Verweij, B. Hauns, W. Loos +4 more
1998Analytical Biochemistry38 citations
Semantic Scholar
Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.
H. Maier-Lenz, B. Hauns, B. Haering, J. Koetting +7 more
1997Seminars in Oncology34 citations
Semantic Scholar
Phase II Study of Combined 5‐Fluorouracil/ Ginkgo biloba Extract (GBE 761 ONC) Therapy in 5‐Fluorouracil Pretreated Patients with Advanced Colorectal Cancer
B. Hauns, B. Häring, S. Köhler, K. Mross +1 more
2001Phytotherapy Research27 citations
Semantic Scholar
Phase II Study with 5-Fluorouracil and Ginkgo biloba Extract (GBE 761 ONC) in Patients with Pancreatic Cancer
B. Hauns, B. Häring, Stephan Köhler, K. Mross +2 more
1999Arzneimittelforschung25 citations
Semantic Scholar
The Oral, Once‐Daily Phosphodiesterase 4 Inhibitor Roflumilast Lacks Relevant Pharmacokinetic Interactions With Inhaled Budesonide
R. Hermann, W. Siegmund, T. Giessmann, K. Westphal +6 more
2007Journal of clinical pharmacology23 citations
Semantic Scholar
Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
T. Bethke, T. Giessmann, K. Westphal, A. Weinbrenner +7 more
2006International journal of clinical pharmacology and therapeutics22 citations
Semantic Scholar
Clinical phase I study with one-hour paclitaxel infusion.
K. Mross, B. Hauns, B. Häring, T. Bauknecht +3 more
1998Annals of Oncology18 citations Open access
Semantic Scholar
Pharmacokinetics and safety of Roflumilast, a once-daily, oral, selective PDE4 inhibitor, and its active metabolite Roflumilast N-oxide in healthy subjects
A. Huennemeyer, B. Hauns, M. David, G. Böhmer +5 more
200415 citations Open access
Semantic Scholar
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
R. Hájek, L. Pour, M. Ozcan, Jesús Martin Sánchez +10 more
2019European Journal of Haematology14 citations Open access
Semantic Scholar
Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.
M. Bitzer, M. Horger, T. Ganten, U. Lauer +16 more
201210 citations
Semantic Scholar
First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study).
B. von Tresckow, Stefan Gundermann, D. Eichenauer, W. Aulitzky +12 more
20149 citations
Semantic Scholar
Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study.
M. Bitzer, M. Horger, T. Ganten, J. Siveke +12 more
2012Journal of Clinical Oncology7 citations
Semantic Scholar
A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors.
A. Brunetto, J. Ang, R. Lal, D. Olmos +6 more
2009Journal of Clinical Oncology7 citations
Semantic Scholar
First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): The SHELTER study.
M. Bitzer, M. Horger, M. Ebert, T. Ganten +6 more
20105 citations
Semantic Scholar
Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor.
J. Walewski, E. Paszkiewicz-Kozik, G. Borsaru, A. Moicean +7 more
20105 citations
Semantic Scholar
A randomized, double-blind phase III study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease.
D. Miklos, M. Jagasia, H. Greinix, B. Ko +7 more
20173 citations
Semantic Scholar
Overcoming the proliferation rate paradox: Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205.
K. Mross, Dirk Scharr, H. Richly, S. Bauer +7 more
20153 citations
Semantic Scholar
Clinical update on a phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): The SHELTER study.
M. Bitzer, M. Horger, Tom M. Ganten, Matthias P. Ebert +10 more
2011Journal of Clinical Oncology3 citations
Semantic Scholar
Clinical update on the SHELTER study: A phase I/II trial of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC).
M. Bitzer, M. Horger, Tom M. Ganten, M. Ebert +6 more
2011Journal of Clinical Oncology3 citations
Semantic Scholar
Resminostat in relapsed or refractory Hodgkin Lymphoma: Initial results of the SAPHIRE phase II trial with a novel oral histone deacetylase (HDAC) inhibitor
J. Walewski, E. Pasziewicz-Kozik, G. Borsaru, A. Moicean +7 more
20103 citations
Semantic Scholar
Complete Remission in Patients with Pancreatic Cancer: A Rare but Sometimes Achievable Event
T. Kirste, B. Hauns, A. Eichelmann, R. Brinkmann +3 more
1998Oncology Research and Treatment3 citations
Semantic Scholar
Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor
J. de Bono, A. Brunetto, R. Kristeleit, A. Mais +2 more
20092 citations
Semantic Scholar
Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: The SHORE trial.
H. Schulze-Bergkamen, D. Jaeger, H. Kopp, F. Mayer +7 more
20131 citations
Semantic Scholar
542 Centralised analysis of phase I ECG dataset of resminostat, a new oral histone deacetylase inhibitor (HDACi)
B. Hauns, A. Mais, R. Jankowsky, B. Hentsch +1 more
20101 citations
Semantic Scholar
393 POSTER First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies
J. Ang, B. Hauns, A. Mais, A. Parker +5 more
20081 citations
Semantic Scholar
Pharmacokinetics of the selective PDE4 inhibitor Roflumilast and its active metabolite Roflumilast N-oxide are not affected by concomitant budesonide, salbutamol, or erythromycin☆
B. Hauns, A. Huennemeyer, W. Siegmund, J. Waitzinger +3 more
20041 citations Open access
Semantic Scholar
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
C. Buske, A. Tedeschi, J. Trotman, R. García-Sanz +16 more
2023Future Oncology0 citations Open access
Semantic Scholar
Patient-Reported Outcomes from Patients with Waldenstrom Macroglobulinemia Treated with Ibrutinib-Rituximab: Results from iNNOVATE Study
J. Matous, A. Tedeschi, M. Dimopoulos, J. Trotman +16 more
20190 citations
Semantic Scholar
PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY
A. Tedeschi, M. Dimopoulos, J. Trotman, Ramón García-Sanz +16 more
2019Hematological Oncology0 citations
Semantic Scholar
PF614 PATIENT-REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB-RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)
A. Tedeschi, M. Dimopoulos, J. Trotman, R. García-Sanz +16 more
2019HemaSphere0 citations Open access
Semantic Scholar
Centralized analysis of phase II ECG dataset of resminostat, an orally available histone-deacetylase inhibitor (HDACi).
B. Hauns, H. Schulze-Bergkamen, D. Jaeger, H. Kopp +5 more
20140 citations
Semantic Scholar
Combination Treatment of Sorafenib and Resminostat, a new HDAC Inhibitor, in Patients with Sorafenib-resistant Hepatocellular Carcinoma (HCC) – Results of the Dose-Escalation Phase
M. Bitzer, M. Horger, T. Ganten, J. Siveke +10 more
20120 citations
Semantic Scholar
540 Clinical phase II development of resminostat, a novel HDAC inhibitor
R. Jankowsky, A. Mais, S. Henning, B. Hauns +1 more
20100 citations
Semantic Scholar
Central ECG analysis of resminostat, a new oral histone deacetylase inhibitor (HDACi), in clinical development as anticancer compound.
B. Hauns, A. Mais, R. Jankowsky, Bernd Hentsch +1 more
20100 citations
Semantic Scholar
First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC) – the SHELTER Study
M. Bitzer, M. Horger, M. Ebert, T. Ganten +6 more
20100 citations
Semantic Scholar
Integrative COPD Biomarker Studie
G. Grentzmann, H. Heinzerling, S. Wollin, B. Hauns +7 more
20060 citations
Semantic Scholar
OP0079 Pain, psychological status, sleep disturbance, and serum concentration of 5-hydroxytryptamine in patients with primary fibromyalgia and chronic low back pain – a comparative study
P. Hrycaj, B. Hauns, K. Ovenhausen, P. Mennet +1 more
20010 citations
Semantic Scholar
Clinical and pharmacokinetic phase I study with taxol® given as short 1-hour intravenous infusion
K. Mross, B. Häring, B. Hauns, H. Maier-Lenz +4 more
19970 citations
Semantic Scholar
Phase II study with 5-fluorouracil and Ginkgo Biloba extract in patients with pancreas CA
H. Stauder, R. Häring, B. Hauns, J. Kuhlmann +4 more
19970 citations
Semantic Scholar
[A new measuring device for computer-assisted imaging of the form and flexibility of the spine].
B. Hauns, K. Ovenhausen, P. Hase, W. Lorenzen +3 more
1994Zeitschrift für Rheumatologie (Print)0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Mais×18
Invite
A. Mais — researcher profile on SciRah
B. Hentsch×13
Invite
B. Hentsch — researcher profile on SciRah
M. Bitzer×10
Invite
M. Bitzer — researcher profile on SciRah
R. Jankowsky×9
Invite
R. Jankowsky — researcher profile on SciRah

×7

Invite

M. Horger — researcher profile on SciRah

Invite

T. Ganten — researcher profile on SciRah

Invite

U. Lauer — researcher profile on SciRah

Invite

S. Henning — researcher profile on SciRah

Invite

R. Hermann — researcher profile on SciRah

Invite

K. Zech — researcher profile on SciRah

Invite

T. Bethke — researcher profile on SciRah

Invite

K. Mross — researcher profile on SciRah